Acronyms and Abbreviations

Updated March 17, 2026

A/G	albumin/globulin
AAHI	Access to Advanced Health Institute
Ab	antibody
ACC/AHA	American College of Cardiology/American Heart Association
ACIP	Advisory Committee on Immunization Practices
ACTG	Advancing Clinical Therapeutics Globally (formerly AIDS Clinical Trials Group)
ACT-UP	AIDS Coalition to Unleash Power
Ad	adenovirus
Ad4	adenovirus type 4
ADA	antidrug antibody
ADCC	antibody-dependent cellular cytotoxicity / antibody-dependent cell-mediated cytotoxicity
ADCD	antibody-dependent complement deposition
ADCP	antibody-dependent cellular phagocytosis
ADHD	attention-deficit/hyperactivity disorder
ADNP	antibody-dependent neutrophil phagocytosis
AE	adverse event
AEC	absolute eosinophil count
AESI	adverse event of special interest
AF	aqueous formulation
Ag	antigen
AHRI	Africa Health Research Institute
AI	avidity index
AIDS	acquired immunodeficiency syndrome
AIDSinfo	UNAIDS website for AIDS information (https://aidsinfo.unaids.org/)
AIPW	augmented inverse probability weighting
AIT	antigen-based immunotherapy
ALP	alkaline phosphatase
ALT	alanine aminotransferase
Alum	aluminum hydroxide suspension
amfAR	American Foundation for AIDS Research
AMI	acute myocardial infarction
AMP	antibody-mediated prevention
ANC	absolute neutrophil count
ANCA	anti-neutrophil cytoplasmic antibody
ANOVA	analysis of variance
AoU	Assessment of Understanding
APC	antigen-presenting cell
APS	antiphospholipid antibody syndrome
aPTT	activated partial thromboplastin time
ARDS	acute respiratory distress syndrome
ARS	acute retroviral syndrome
ART	antiretroviral therapy
ARV	antiretroviral
ASA	acetylsalicylic acid
ASCVD	atherosclerotic cardiovascular disease
ASO	AIDS service organization
AST	aspartate aminotransferase
ATI	analytical treatment interruption
AUC	area under the curve
AUC-MB	area under the magnitude-breadth curve
AVAC	AIDS Vaccine Advocacy Coalition
AVEG	AIDS Vaccine Evaluation Group (predecessor network to HVTN)

AVRS	AIDS Vaccine Research Subcommittee (NIAID)
BAL	bronchoalveolar lavage
BAMA	binding antibody multiplex assay
BAMA-AI	binding antibody multiplex assay avidity index
BARC	Bioanalytical Research Corporation South Africa
BCG	bacille Calmette-Guérin (preventive TB vaccine)
BCR	B-cell receptor
BLI	biolayer interferometry
BM	bone marrow
BMGF	Bill and Melinda Gates Foundation
BMI	body mass index
bnAb	broadly neutralizing antibody
BP	blood pressure
BRA	behavioral risk assessment
BRR	Bill of Rights and Responsibilities, for HIV or TB vaccine trials
BSL	biosafety level
CAB	Community Advisory Board
CAG	Countermeasures Accelerations Group
CAPRISA	Centre for the AIDS Programme of Research in South Africa
CARD	current activity reporting dashboard
cART	combination antiretroviral therapy
CAVD	Collaboration for AIDS Vaccine Discovery
CAVIMC	Comprehensive Antibody Vaccine Immune Monitoring Consortium
CBC	complete blood count
CBMC	cord blood mononuclear cell
CBO	community-based organization
CBPR	community-based participatory research
CC	Clinic Coordinator
CD4bs	CD4 binding site
CDA	confidential disclosure agreement
CDC	US Centers for Disease Control and Prevention
CDM	Clinical Data Manager (SDMC)
CDR	complementarity-determining region
CDRL3	complementarity-determining region light chain 3
CE	Conformité Européenne (European Conformity)
CEU	Community Engagement Unit (HVTN LOC)
CFR	Code of Federal Regulations (US)
CFU	colony forming unit
CGG	chronic granulomatous disease
cGMP	current Good Manufacturing Practice
CHAVI-ID	Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (NIAID)
CHIL	Cape Town HVTN Immunology Lab
CHO	Chinese hamster ovary
CI	confidence interval
CIOMS	Council for International Organizations of Medical Sciences
CKD-Epi	Chronic Kidney Disease Epidemiology Collaboration
CL	clearance
CM	Clarification Memo
CMA	conditional marketing authorization
Cmax	maximum concentration
CMC	chemistry, manufacturing, and control
CMIA	chemiluminescent microparticle immunoassay
CMM	Core Medical Monitor
cMRI	cardiac magnetic resonance imaging
CMV	cytomegalovirus
COMPASS	combinatorial polyfunctionality analysis of antigen-specific T-cell subsets

ConC	consensus clade C sequence
CONSORT	Consolidated Standards of Reporting Trials
COPD	chronic obstructive pulmonary disease
Core	Leadership and Operations Center (HVTN) (see LOC)
COVAX	COVID-19 Vaccines Global Access
COVID-19	Coronavirus disease 2019
CoVPN	COVID-19 Prevention Network
CP	Community Partners (a cross-network CAB convened by HANC)
CpG	cytidine phosphoguanosine
CRAN	Comprehensive R Archive Network
CRF	case report form
CRMS	Clinical Research Management System
CRO	Contract Research Organization
CRP	C-reactive protein
CRPMC	Clinical Research Products Management Center
CRS	Clinical Research Site
cryoEM	cryo-electron microscopy
cryoEMPEM	cryo-electron microscopy–based polyclonal epitope mapping
CS	concept sheet
CSF	cerebrospinal fluid
CSIO	Clinical Study Information Office (DAIDS)
CSR	central specimen repository
CSR	clinical study report
CSS	Clinical Safety Specialist (HVTN)
CSW	commercial sex worker
CTA	Clinical Trials Agreement
CTCAE	Common Terminology Criteria for Adverse Events
CTI	clinical trials insurance
CTL	cytotoxic T lymphocyte
CTM	Clinical Trials Manager (HVTN)
CTU	clinical trials unit
d/v	dose/volume
DAERS	DAIDS Adverse Experience Reporting System
DAIDS	Division of AIDS (NIAID)
DAIDS-ES	DAIDS Enterprise System
DC	dendritic cell
DHHS	see HHS
DHVI	Duke Human Vaccine Institute
DLT	dose-limiting toxicity
DM	dermatomyositis syndrome
DM	diabetes mellitus
DM	Discovery Medicine (HVTN)
DMC	Data Monitoring Committee
DMF	Drug Master File
DMG	dimyristoyl glycerol
DMQ	data management quality
DOH	Department of Health
DOV	discontinuation of vaccination
DRE	disease-related event
DS	disulfide
DS	drug substance
DSMB	Data and Safety Monitoring Board (NIAID)
DSPC	1,2-Distearoyl-sn-glycero-3-phosphocholine
DSPC	distearoylphosphatidylcholine
DSPG	1,2-Distearoyl-sn-glycero-3-phosphoglycerol
DSUR	Development Safety Update Report

DTaP	diphtheria, tetanus, and acellular pertussis vaccine
DTH	delayed-type hypersensitivity
E6(R3)	ICH Harmonised Guideline: Guideline for Good Clinical Practice E6(R3)
EAC	Endpoint Adjudication Committee
EAE	expedited adverse event
ebnAb	engineering broadly neutralizing antibody
EC	Ethics Committee
ECG	electrocardiogram
ECLIA	electrochemiluminescence immunoassay
eCTD	electronic Common Technical Document
EDC	electronic data capture
eGFR	estimated glomerular filtration rate
EIA	enzyme immunoassay
EKG	see ECG
ELISA	enzyme-linked immunosorbent assay
ELISpot	enzyme-linked immunosorbent spot
EM	electron microscopy
EMH	extramedullary hematopoiesis
EMPEM	electron microscopy–based polyclonal epitope mapping
EMT	Executive Management Team (HVTN)
Env	HIV-1 envelope protein
EnvSeq-1	sequential gp120 Env immunogen
EP	electroporation
EPI	Expanded Program on Immunization (WHO)
EQC	external quality control
ESI	early-stage investigator
ETWG	Efficacy Trials Working Group (HVTN)
EUA	Emergency Use Authorization
EUL	Emergency Use Listing
EUROVACC	European Vaccine Effort Against HIV/AIDS
F2F	face-to-face [meeting]
Fab	fragment antigen-binding
FAS	full analysis set
FBO	faith-based organization
Fc	fragment crystallizable
FcR	fragment crystallizable receptor
FcRn	neonatal fragment crystallizable receptor
FDA	US Food and Drug Administration
FFU	focus-forming unit
FHCC	Fred Hutchinson Cancer Center (also known as Fred Hutch)
FIH	first-in-human
FNA	fine-needle aspiration
FP	fusion peptide
FP8v1-rTTHC	fusion peptide conjugate vaccine
FP8v2	eight N-terminal fusion peptide residues
FPA	Full Protocol Amendment
FPR	false-positive rate
FR3	framework 3
FRR	Full Regulatory Review (DAIDS RAB)
FS	functionality score
FTC	emtricitabine
GC	germinal center
GCLP	Good Clinical Laboratory Practice
GCP	Good Clinical Practice
GEE	generalized estimating equation
GINA	Genetic Information Nondiscrimination Act

GL	germline
GLA	glucopyranosyl lipid A
GLA-SE	glucopyranosyl lipid A stable emulsion
GLP	Good Laboratory Practice
GMP	good manufacturing practice
GMT	geometric mean titer
GPA	granulomatosis with polyangiitis
GPP	Good Participatory Practices
GSK	Glaxo Smith Kline / GlaxoSmithKline
GTI	genital tract infection
GTL	GranToxiLux
H&E	haematoxylin and eosin
HA	hemagglutinin
HAART	highly active antiretroviral therapy
HANC	Office of HIV/AIDS Network Coordination (DAIDS)
HBIG	hepatitis B immunoglobulin
HBsAg	hepatitis B surface antigen
HBV	hepatitis B virus
HC	heavy chain
HCD	higher-energy collisional dissociation
HCDR3	heavy chain complementarity-determining region 3 / heavy chain third complementarity determining region
HCMV	human cytomegalovirus
H-CORE	Department of Health and Human Services Coordination Operations and Response Element
HCRISA	Hutchinson Centre Research Institute of South Africa
HCV	hepatitis C virus
HEp-2	human epithelial type 2
HEU	exposed to but without HIV (replaces “HIV exposed-uninfected”)
Hg	mercury
Hgb	hemoglobin
HHS	US Department of Health and Human Services
Hib	Haemophilus influenza type B
HIPAA	Health Insurance Portability and Accountability Act
HIT	heparin-induced thrombocytopenia
HIV	human immunodeficiency virus
HIVNET	HIV Network for Prevention Trials (NIAID, closed October 1999)
HLA	human leukocyte antigen
HPTN	HIV Prevention Trials Network
HPV	human papilloma virus
HSML	HIV Seromolecular Laboratory
HSML-NICD	HIV Seromolecular Laboratory – NICD
HSP	Human Subjects Protection
HSV2	herpes simplex virus type 2
HVTN	HIV Vaccine Trials Network
IA	immediate ancestor
IA	interim analysis
IAS	International AIDS Society
IAS-USA	International Antiviral Society – USA
IAVI	International AIDS Vaccine Initiative
IB	Investigator’s Brochure
IBC	Institutional Biosafety Committee
IC	inhibitory concentration
IC50	half-maximal inhibitory concentration / median inhibitory concentration
IC80	80% inhibitory concentration
ICABA	infected cells antibody-binding assay
ICF	informed consent form

ICH	International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
ICS	intracellular cytokine staining
ID	intradermal
IDR	immunodominant region
IDRI	Infectious Disease Research Institute
IEC	Independent Ethics Committee
IFN	interferon
IFN-α	interferon-alpha
IFN-γ	interferon-gamma
Ig	immunoglobulin
IgA	immunoglobulin subtype A
IgG	immunoglobulin subtype G
IGRA	interferon-gamma release assay
IHC	immunohistochemistry
IL	interleukin
IL-12	interleukin 12
IL-6	interleukin 6
IM	intramuscular
IMC	infectious molecular clone
IMPAACT	International Maternal Pediatric Adolescent AIDS Clinical Trials
IN	intranasal
IND	Investigational New Drug (FDA)
INH	isoniazid
INR	international normalized ratio
IoR	Investigator of Record
IP	investigational product
IP-10	interferon-gamma-inducible protein 10
IPV	injectable polio vaccine
IQC	internal quality control
IQR	interquartile range
IR	intrarectal
IRB	Institutional Review Board
IRM	immune response modifier
IRR	infusion-related reaction
IRT	interactive response technology
IS	immunogenicity subcohort / immunogenicity subset
IS	implementation science
ISCOM	immune stimulating complex
ITP	idiopathic thrombocytopenic purpura
ITT	intent-to-treat
IUD	intrauterine device
IV	intravenous
JNJ	Johnson & Johnson
JSRC	Joint Scientific Review Committee (HVTN/HPTN)
kDa	kilodalton
kg	kilogram
KI	knock-in
KLH	keyhole limpet hemocyanin
KO	knockout
KPI	key performance indicator
KZN	KwaZulu Natal (South Africa)
L	leucine
Lab Ops	Laboratory Operations (HVTN)
Lab Sc	Laboratory Science (HVTN SDMC)
LABA	long-acting beta agonist

LAM	lipoarabinomannan
LC	Laboratory Center (HVTN)
LC	light chain
LC-MS	liquid chromatography mass spectrometry
LC-MS/MS	liquid chromatography-tandem mass spectrometry
LDH	lactate dehydrogenase
LLOQ	lower limit of quantification
LN	lymph node
LNP	lipid nanoparticle
LOA	Letter of Amendment
LOC	Leadership and Operations Center (HVTN) (see Core)
LPLV	last participant last visit
L-S	leucine-serine
LSM	least square means
LTFU	long-term follow-up
LTFU	loss to follow-up
LTR	long-terminal repeat
M.tb	*Mycobacterium tuberculosis*
MAAE	medically attended adverse event
mAb	monoclonal antibody
MAD130	Teleflex Medical LMA MAD Nasal Intranasal Mucosal Atomization Device
MAR	missing at random
MB	magnitude breadth
MBL	mannose-binding lectin
MCAR	missing completely at random
MCC	Medicines Control Council (South Africa)
mcg	microgram (see mμ)
MCP-1	monocyte chemoattractant protein 1
MCV	mean corpuscular volume
mDC	myeloid dendritic cell
MDP	muramyl dipeptide
MedDRA	Medical Dictionary for Regulatory Activities
MFI	mean fluorescence intensity
mg	milligram
MHC	major histocompatibility complex
MHRP	US Military HIV Research Program
MIF	macrophage migration inhibitory factor
MIMOSA	mixture models for single-cell assays
MIT	Massachusetts Institute of Technology
MITT	modified intent-to-treat
mIU	mill-international unit
mL	milliliter
MLV	murine leukemia virus
MMR	measles, mumps, and rubella
MO	Medical Officer (DAIDS)
MOB	Monitoring Operations Branch (DAIDS)
MOP	Manual of Procedures (HVTN)
MPER	membrane proximal external region
MPLA	monophosphoryl lipid A
MRC	Medical Research Council (South Africa)
MRI	magnetic resonance imaging
mRNA	messenger ribonucleic acid
MS	mass spectrometry
MSD	mesoscale discovery
MSM	men who have sex with men
MS-MS	tandem mass spectrometry

MTBC	M. tuberculosis complex
MTD	maximum tolerated dose
MTI	monthly trials implementation meeting
MTP-PE	muramyl tripeptide phosphatidylethanolamine
MVA	modified vaccinia Ankara virus
mμ	microgram (see mcg)
NAAT	nucleic acid amplification testing
nAb	neutralizing antibody
NAEPP	National Asthma Education and Prevention Program
NAT	nucleic acid test
NB	nonbinary
NEC	Network Evaluation Committee (HVTN)
NFL	native flexibly linked
NGO	nongovernmental organization
NHP	nonhuman primate
NIAID	National Institute of Allergy and Infectious Diseases (NIH)
NICD	South Africa National Institute for Communicable Diseases
NIH	US National Institutes of Health
NK	natural killer
NLGS	N-linked glycosylation site
NLT	native-like trimer
NNRTI	non-nucleoside reverse transcriptase inhibitor
NOAEL	no-observed-adverse-effect level
NOCD	new onset chronic disease
NOD	nucleotide-binding oligomerization domain
NP	nanoparticle
NSAID	nonsteroidal anti-inflammatory agent
NZW	New Zealand White (rabbit)
OAR	Office of AIDS Research (NIH)
OARAC	Office of AIDS Research Advisory Committee (NIH)
OBA	Office of Biotechnology Activities (NIH)
OCGR	Office of Communications and Government Relations (NIAID)
OCSO	Office of Clinical Site Oversight (DAIDS)
ODN	oligodeoxynucleotide
OG	Oversight Group (NIAID)
OHRP	Office for Human Research Protections (HHS)
OPCRO	Office for Policy in Clinical Research Operations (DAIDS)
OPV	oral polio vaccine
OWS	Operation Warp Speed
PAB	Pharmaceutical Affairs Branch (DAIDS)
pAb	polyclonal antibody
PAC	Protocol Allocation Committee
PAGE	polyacrylamide gel electrophoresis
PBMC	peripheral blood mononuclear cell
PBS	phosphate-buffered saline
PC	Project Coordinator (HVTN)
PCA	principal component analysis
PCR	polymerase chain reaction
PCV	pneumococcal conjugate vaccine
PD	pharmacodynamics
PD	protocol development
PDB	protocol database (HVTN)
pDC	plasmacytoid dendritic cell
PDIM	phthiocerol dimycocerosate
PDM	Protocol Development Manager (HVTN)
PEF	peak expiratory flow

PEG	polyethylene glycol
PEP	post-exposure prophylaxis
PFS	polyfunctionality score
PHRU	Perinatal HIV Research Unit (clinical research site in Soweto, RSA)
PI	Principal Investigator
PID	pelvic inflammatory disease
PIMD	potential immune-mediated disease (see PIMMC)
PIMMC	potential immune-mediated medical condition
PK	pharmacokinetics
PL	Product Lead (DAIDS VTRB) (see PO)
PLGA	polylactic-co-glycolic acid
PLWH	people living with HIV
PLWoH	people living without HIV
PM	polymyositis syndrome
PM	Project Manager
PO	Product Officer (DAIDS VTRB) (see PL)
POD	prevention of disease
POPIA	Protection of Personal Information Act (South Africa)
popPK	population pharmacokinetic
PP	per-protocol
PPD	Pharmaceutical Product Development (DAIDS)
PPD	purified protein derivative
PrEP	pre-exposure prophylaxis
ProPEP	Protection of Participants, Evaluation, and Policy (DAIDS)
PRT	Primary Review Team
PSRC	Prevention Science Review Committee (DAIDS)
PSRT	Protocol Safety Review Team
PT	Preferred Term (MedDRA)
PT	Protocol Team (HVTN)
PTE	potential T-cell epitope
pTfh	peripheral T follicular helper cell
PTID	participant identification [number]
PTL	Protocol Team Leader (HVTN)
PVG	pharmacovigilance
PVMA	pediatric vaccine multiplex assay
PWH	people with HIV
QC	quality control error
QFT	QuantiFERON-TB
qPCR	quantitative polymerase chain reaction
QS-21	*Quillaja saponaria* fraction 21
QVOA	quantitative viral outgrowth assay
RA	Regulatory Authority (see RE)
RAB	Regulatory Affairs Branch (DAIDS)
RAC	Recombinant DNA Advisory Committee (NIH)
RBC	red blood cell
RBD	receptor-binding domain
RCT	randomized controlled trial
RE	Regulatory Entity (see RA)
recEnv	recombinant HIV envelope protein
Reg	Regulatory Affairs (HVTN)
RFU	ready for use
RhCMV	rhesus cytomegalovirus
RM	rhesus macaque
RML	Regional Medical Liaison (HVTN South Africa and Latin America)
RSA	Republic of South Africa
RSC	Regulatory Support Center (DAIDS)

RSI	Reference Safety Information
RSV	respiratory syncytial virus
RT-PCR	reverse transcription polymerase chain reaction
rTTHC	recombinant tetanus toxoid heavy chain fragment C
RTV	rotavirus (see RV)
RUTI	recurrent urinary tract infection
RV	rotavirus (see RTV)
RVE	relative vaccine efficacy
S	serine
S	spike protein
SAAVI	South African AIDS Vaccine Initiative
SAE	serious adverse event
SAHPRA	South African Health Products Regulatory Authority
SAIL	South Africa Immunology Laboratory
SAIL-NICD	South Africa Immunology Laboratory – NICD
SAMRC	South African Medical Research Council
SAP	Statistical Analysis Plan
SAR	Sponsor's Authorized Representative
SARS-CoV-2	severe acute respiratory syndrome coronavirus 2
SAS	Statistical Analysis System
SATVI	South African Tuberculosis Vaccine Initiative
SBS-CEU	Social & Behavioral Sciences and Community Engagement Unit (HVTN)
SBWG	Social and Behavioral Sciences Working Group
SC	subcutaneous
SCHARP	Statistical Center for HIV/AIDS Research and Prevention (serves as HVTN's SDMC, Fred Hutch)
SCID	severe combined immunodeficient
scNP	sortase A-conjugated ferritin nanoparticle
SCORE	Site Clinical Operations and Research Essentials
SD	standard deviation
sD	synthetic DNA
SDMC	Statistical and Data Management Center
SE	stable emulsion
SEG	Special Emphasis Group (Laboratory)
SFC	spot-forming cell
SFU	spot-forming unit
SGC	Scientific Governance Committee (HVTN)
SHD	standard human dose
SHIV	simian-human immunodeficiency virus
SHM	somatic hypermutation
SIB	suicidal ideation and behavior
SICF	sample informed consent form
sIRB	single Institutional Review Board
SIV	simian immunodeficiency virus
SLE	systemic lupus erythematosus
SMB	Safety Monitoring Board (HVTN)
SMC	Safety Monitoring Committee
SMNP	saponine/monophosphoryl lipid A nanoparticle
SMQ	Standard Medical Query
SoA	Schedule of Activities
SOP	Standard Operating Procedures
SPR	surface plasmon resonance
SPT	Safety and Pharmacovigilance Team (DAIDS)
SRA	Statistical Research Associate
SRC	Scientific Review Committee (HVTN)
SS	safety subset
SS	Sjogren's syndrome

SSc	systemic sclerosis
SSD	systemic scleroderma
SSI	Statens Serum Institute
SSP	Study-Specific Procedures
SSR	Special Situation Report
SST	serum-separating tube
STI	sexually transmitted infection
SUSAR	Suspected, Unexpected Serious Adverse Reaction
SVA-MLV	simian virus amphotropic murine leukemia virus
SWFI	Sterile Water for Injection
SWI	Sterile Water for Injection
t/f	transmitted/founder
T1/2	terminal half-life
TAF	tenofovir alafenamide
TAG	Treatment Action Group
TAT	temporal artery thermometry
TB	tuberculosis
TBS	Tris-buffered saline
TBVI	Tuberculosis Vaccine Initiative
TCID	tissue culture infectious dose
TCID50	median tissue culture infectious dose
TCR	T-cell receptor
TCR	T-cell repertoire
TCR	tissue cross-reactivity
TDF	tenofovir disoproxil fumarate
TDS	Ichor Medical Systems TriGrid Delivery System
TE	Technical Editor (HVTN)
TE	treatment-emergent
TEAE	treatment-emergent adverse event
TEM	transmission electron microscopy
Tfh	T follicular helper
TLR	toll-like receptor
Tmax	time to maximum concentration
TMLE	targeted minimum loss-based estimation
TNF-α	tumor necrosis factor alpha
TPT	tuberculosis preventive treatment
TTS	thrombosis with thrombocytopenia syndrome
UCA	unmutated common ancestor
UFO	uncleaved prefusion-optimized
ULN	upper limit of normal
UNAIDS	Joint United Nations Programme on HIV/AIDS
USAID	United States Agency for International Development
USMHRP	US Military HIV Research Program
USP	United States Pharmacopeia
UW-VSL	University of Washington – Virology Specialty Laboratory
V	variable loop
V1	variable loop 1
V2	variable loop 2
V3	variable loop 3 / third variable loop
V3G	V3-glycan
VAERS	Vaccine Adverse Event Reporting System (CDC)
VAX300	VaxINator Intranasal Atomization Device
VCMP	Vaccine Clinical Materials Program
VCRB	Vaccine Clinical Research Branch (DAIDS)
Vd	volume of distribution
VE	vaccine efficacy

VH	heavy chain variable domain
VISC	Vaccine Immunology Statistical Center
VISP	vaccine-induced seropositivity
VISR	vaccine-induced seroreactivity
VL	light chain variable domain
VL	viral load
VLP	virus-like particle
VOC	variant of concern
VRC	Dale and Betty Bumpers Vaccine Research Center (NIAID)
VRP	Vaccine Research Program (DAIDS)
VSV	vesicular stomatitis virus
VTRB	Vaccine Translational Research Branch (DAIDS)
w/v	weight per volume
WBC	white blood cell
WHO	World Health Organization
WOCBP	women of childbearing potential
WONCBP	women of non-childbearing potential
WPG	work-practice guidelines
WRAIR	Walter Reed Army Institute of Research
WT	wild-type
β-HCG	beta human chorionic gonadotropin
λz	terminal elimination rate constant